REGENERON PHARMACEUTICALS, INC.

All Holdings — 2025 Q4

AI Portfolio Summary
In 2025 Q4, REGENERON PHARMACEUTICALS, INC. maintained a portfolio of 4 distinct positions. Conversely, REGENERON PHARMACEUTICALS, INC. completely exited their position in Alnylam Pharmaceutic.
PCA Score Concentration Risk
Risk ENB
Total Positions
4
Quarter
2025 Q4
Top Holding
NTLA (98.5%)
Top 10 Concentration
100.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-4 of 4
Stock History Sector / Type Port % Prev % Rank / Prev Conviction Change % Change Influence Shares Mkt Value Avg Cost Price Held 1st Owned Source Source Date Date Reported
NTLA
Intellia Therap...
Healthcare 98.49% 9.13% #1 1
Prev: #2
7.0 no change no change
P
S
3,702,995 $33,289,925 2024 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
ACET
Adicet Bio, Inc...
Healthcare 1.51% 0.11% #2 2
Prev: #4
2.1 -907,672 -93.8%
P
S
60,511 $509,503 2024 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
ALNY
Alnylam Pharmac...
Healthcare 0.00% 90.64%
Sold All 😨
(Was: #1)
0.0 -1,392,303 -100.0%
CLOSED
$— 2024 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
ADVM
Adverum Biotech...
Healthcare 0.00% 0.12%
Sold All 😨
(Was: #3)
0.0 -180,909 -100.0%
CLOSED
$— 2024 Q4 13F Filing 2025-12-31 2026-02-14 (Est.)
Showing 1-4 of 4 holdings

Unlock Full REGENERON PHARMACEUTICALS, INC. Analysis

PRO subscribers get access to all historical quarters, Excel/CSV exports, Portfolio Concentration Analytics (PCA), and Risk-Based ENB.

Full Historical Quarters
Excel & CSV Export
PCA & Risk-Based ENB
Auto Cost Basis
Position Change Alerts
Price-Held Analytics